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Abstract Osteoarthritis (OA), also called degenerative joint disease, is the most fre-
quently occurring chronic musculoskeletal disease, particularly affecting the
aging population. The use of viscosupplementation, i.e. intra-articular (IA)
hyaluronic acid (HA) drug therapy, to treat OA, is growing worldwide, due
to important results obtained from several clinical trials, which reported
IA HA-related improvements in functional activity and pain management.
This review is an update of the IA use of this compound in the treatment of
OA, with clinical evidence from the last few years being discussed and used to
delineate new trends for the future.
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1. Introduction
The principal forms of chronic arthritis can be
grouped as follows: (i) atrophic arthritis with sy-
novial inflammation and erosion or atrophy of
the cartilage and bone (e.g. rheumatoid arthritis
[RA]); and (ii) hypertrophic arthritis, character-
ized by focal loss of cartilage with little evidence
of the typical form of inflammation (it is not a
systemic disease and the ‘inflammatory compo-
nent’ seems to be restricted to the cartilage and
bone), and by growth (hypertrophy) of the adja-
cent bone and soft tissue (i.e. osteoarthritis [OA]).[1]
The term ‘osteoarthritis’ is derived from the Greek
word osteon, meaning ‘of the bone’, arthronmean-
ing ‘joint’, and itis meaning ‘inflammation’. OA
is the most common form of arthritis affecting
the aging population, causing significant pain
and functional disability worldwide.[2] It has been
observed that about one-third of adults show
radiologic signs of OA,[3] although an epidemio-
logic study found clinically significant OA of the
knee, hand, or hip in only 8.9% of adults; knee OA
was themost common type of OA, occurring in 6%
of adults.[4]
Endogenous risk factors for OA of the knee in-
clude age, sex, family history, ethnic origin (OA is
more common in people of European descent), and
post-menopausal changes. Exogenous risk factors
include macrotrauma, repetitive microtrauma, be-
ing overweight, resective joint surgery, and lifestyle
factors (e.g. alcohol and tobacco use).[5] The rela-
tionship between running andOAhas been studied
for a long time in both humans and animals. A
review in 2006 concluded that a moderate level of
running does not increase the risk of knee or hip
OA in healthy people, and that this activity might
even have a protective effect; however, a history of
injury from overuse or acute trauma, running or
excessive running, intrinsic anatomical instability
in the joints, or a high body mass index, can ac-
celerate the onset of OA and cause disability.[6]
OA is a degenerative joint disease character-
ized by an accumulation of mechanical stresses
to joints, leading to the destruction of articular
cartilage. It is caused by a combination of (i) in-
creased degradation of extracellular matrix (ECM;
some members of the matrix metalloproteinase
[MMP] and a disintegrin and metalloproteinase
with thrombospondin motifs [ADAMTS] gene
families have been correlated with the process of
cartilage ECM degradation); (ii) decreased pro-
duction of ECM; and (iii) chondrocyte death.[7]
OA has historically been classified as ‘primary’
if no discernible cause is evident (e.g. related to
age and genetics) and ‘secondary’ if a triggering
factor is apparent (e.g. associated with a history
of joint injury, such as those caused by trauma,
infection, surgery, mineral deposition, or auto-
immune disorders).[6,8] Aggrecan and type II
collagen are the most abundant proteins found in
the ECM, and are both produced by chondro-
cytes. Their destruction is crucial in the alteration
of cartilage homeostasis and ECM destruction
in OA. Mechanical stress, aging, genetic back-
ground, inflammation, and phenotypic changes
of chondrocytes are thought to influence the
pathogenesis of OA[9] (figure 1).
During the osteoarthritic process, it has been
observed that articular chondrocytes exhibit an
age-related increase in cytokine and MMP levels,
a decline in the synthetic capacity of growth fac-
tors, and an increase in the features of senescence
(e.g. increased activity of senescence-associated
b-galactosidase, p53, p21, and p16, and telomere














Fig. 1. Risk factors involved in the osteoarthritic process.[10-13]
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senescence is caused by the reactive oxygen spe-
cies (ROS), and ROS are induced by the me-
chanical stress loaded onto the chondrocyte,
these molecules may play a key role in the
pathogenesis of OA.[14]
Drugs, such as glucocorticoids and NSAIDs,
have been widely used for the treatment of OA;
however, none of these agents provide a complete
treatment and they have all been associated with
adverse effects. Recently, new strategies, such as
anti-cytokine therapy, gene therapy, delivery of
growth factors, stem-cell therapy, and new lu-
bricant agents, such as lubricin, have been pro-
posed.[15] The use of viscosupplementation (i.e.
intra-articular [IA] hyaluronic acid [HA] drug
therapy) to treat OA is growing worldwide due to
important results obtained from several clinical
trials reporting improvements in functional ac-
tivity and pain management. HA is a constitutive
component of matrix cartilage, which plays a key
role in the maintenance of joint homeostasis. HA
is also a biologically active component, secreted
by chondrocytes, that protects the cartilage from
degradation by interacting with MMPs and pain
mediators. This review provides an up-to-date
analysis of the IA HA for the treatment of OA.
1.1 Search Criteria
Data from clinical trials published between
January 2007 and April 2010 that involved the
use of IA HA for the treatment of OA were de-
rived from a literature search in MEDLINE and
PubMed using the keyword ‘‘hyaluronic acid’’




In 1934, Karl Meyer isolated an unknown
glycosaminoglycan from the vitreous humor of
the bovine eye and proposed, for convenience, to
name it ‘hyaluronic acid’ (derived from hyaloid
[vitreous] and uronic acid).[16] Originally, this
compound was known as hyaluronan when refer-
ring to its synthesis in vivo, and HA when refer-
ring to research performed in vitro.[16] However,
the terms are now used synonymously; the com-
pound is also sometimes referred to as hyaluronate.
2.2 Pharmacologic Properties
HA is a non-sulfated, naturally occurring gly-
cosaminoglycan with distinct physicochemical
properties, consisting of alternately repeating
D-glucuronic acid and N-acetylglucosamine
units (figure 2).[17] HA exists naturally in various
animal tissues, including rooster combs (the lar-
gest content of HA), shark skin, bovine eyeballs,
bovine nasal cartilage, rabbit brain, and rabbit
heart, and in various human tissues, including the
umbilical cord, synovial fluid (SF), vitreous
body, dermis, epidermis, thoracic lymph, urine,
and serum.[18] However, the highest amounts of
HA in the human body are found in the ECM of
soft connective tissues.[19]
The two types of HA currently available are
(i) low molecular weight HA (LMW HA) –
hyaluronans, sodium hyaluronans, or hyaluro-
nates (molecular weight 0.5–3.6million Da); and
(ii) high molecular weight HA (HMW HA) -
chemically crosslinked hyaluronan (molecular
weight 6.0 million Da).[20] HA physicochemical
characteristics (i.e. hydrophilic, rheologic, signal-
ing, and viscoelastic properties) and biologic
functions (e.g. involvement in embryogenesis, in-
flammation, metastasis, tumor progression, tis-
sue turnover, and wound healing) depend on its
molecular weight and interactions with specific
binding proteins called ‘hyaladherins’. These in-
teractions modify the conformation of HA. The
best characterized hyaladherins are structural
hyaluronan-binding proteins of the ECM (i.e.
link protein and the aggregating proteoglycans
aggrecan, versican, brevican, and neurocan), and























Fig. 2. The chemical structure of hyaluronic acid.
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molecules all have structurally similar hyaluronan-
binding domains, which are termed link modules.
The receptor for hyaluronic acid-mediated mo-
tility (RHAMM) is another hyaladherin, but this
molecule does not have link modules.[21]
HA is involved in various biologic processes
because it stimulates cell migration, differentia-
tion, and proliferation, and regulates ECM orga-
nization and metabolism.[22] In the cartilage, HA
plays an important structural role in the matrix,
forming an aggregation center for aggrecan, a
large chondroitin sulfate proteoglycan that re-
tains its macromolecular assembly in the matrix
due to specific HA-protein interactions.[23] Car-
tilage homeostasis and modulation of cartilage
metabolism is maintained by the interaction of
HA with the CD44 receptor on chondrocytes
(CD44 isoform), suggesting that disruption of
these interactions may promote matrix remodel-
ing.[24,25] This receptor is also present in the os-
teocyte plasma, basolateral membrane, and the
cytoplasmic processes of active osteoblasts. The
interaction of theCD44 receptor withHA restricts
osteoblast-mediated osteoclastogenesis.[26-28]
HA interacts with other biomacromolecules,
such as collagen, to promote ECM assembly. HA
can also interact with cells through receptors
on the plasmatic membrane, such as the CD44
receptor, which activates several biologic effects,
such as modulation of angiogenic processes, in-
duction of pro-inflammatory MMP expression,
enhancement of cell motility and invasion, and
amplification of cell proliferation.[29] Moreover,
there is evidence that the interaction between
HA and CD44 plays a key role at several stages
of embryogenesis,[30] as well as in the develop-
ment of adult tissues.[31-33] HA also plays an
important role in signal transduction, and the
molecule is associated with cancer invasiveness
and metastasis.[34]
In addition, hyaluronan possesses chondrop-
rotective effects, whichmake it useful for the treat-
ment of OA and RA (sections 2.2.1 and 2.3). The
cell surface receptors of hyaluronan are involved
in (i) the inhibition of the catabolic actions exerted
by pro-inflammatory cytokines and matrikines
(matrix degradation products), which are known
to be increased in OA and RA joints; and (ii) the
induction of catabolic enzymes (e.g. collagenase and
aggrecanase) that cause cartilage degradation.[35]
The use of HA and HA-based scaffolds in the
repair of ligament, cartilage, adipose tissue, bone,
and osteochondral defects has been investigated
in various tissue engineering studies.[36] In addi-
tion, clinical data on the efficacy of HA scaffolds
in the tissue engineering of cartilage[37,38] and ar-
tery regeneration[39] have been reported.
2.2.1 In Osteoarthritis or Rheumatoid Arthritis
From a clinical perspective, patients with OA
have been shown to have a variable degree of
synovitis, and it is thought that several cytokines
and other mediators, particularly tumor necrosis
factor (TNF)-a and interleukin (IL)-1, may play
a key role in both synovial inflammation, and in
the activation of chondrocytes and synovial fi-
broblasts.[40] These cytokines can stimulate their
own production, and induce synovial cells and
chondrocytes to produce IL-6, IL-8, and leuko-
cyte inhibitory factor, along with proteases and
prostaglandins. In fact, it has been hypothesized
that TNFa and IL-1 are key mediators of in-
flammation and articular cartilage destruction,
supporting a future possibility of anticytokine
therapy in OA or the design of specific disease-
modifying anti-OA drugs.[41]
A recent study performed in 82 patients, aged
90 years, showed that low innate production of
the pro-inflammatory cytokines IL-1b and IL-6
was associated with the absence of OA in old age.
In particular, the absence of hand OA was associ-
ated with low innate production of IL-6 and IL-1
receptor antagonist, and the absence of hip OA
was associated with low IL-1b production. These
findings suggest the presence of protective factors
against OA development, and underline the im-
portance of cytokine pathways in the patho-
physiology of this degenerative condition.[42]
Joint destruction in RA is caused by the pro-
inflammatory cytokine-stimulated (e.g. IL-1b)
production of MMPs by rheumatoid synovial
fibroblasts (RSFs).[43] In contrast, TNF-a or IL-
1b-stimulated production of hyaluronan inhibits
MMP-1 production by RSFs, suggesting a ther-
apeutic role of HA in the treatment of rheuma-
toid joints.[44] In addition, the binding of HA to
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CD44 is directly involved in the suppression of
MMP-1 production.[45]
In normal SF, the high concentration ofHMW
HA is responsible for joint lubrication and shock
absorption. The HA viscoelastic behavior differs
depending on the force applied. If a shear stress is
applied, HA acts as a lubricant, becoming less
viscous and allowing free and easy movements.
However, if a compressive force is applied, HA
acts as a shock absorber, preventing injury to
the joint. HMW HA in the SF also provides a
renewed source of HA to joint tissues, thus re-
storing the normal levels.[46] Under inflammatory
conditions of arthritic diseases, such as OA or
RA, HMW HA is degraded by ROS, which re-
duces its viscosity and impairs its lubricant and
shock absorbing properties, leading to deterio-
rated joint movement and pain.[47] It has been
speculated that the removal of pathologic osteo-
arthritic SF and its replacement with HA-based
products (viscosupplementation) may have ben-
eficial therapeutic effects (section 2.3).[48]
HMW HA in the SF is also essential for the
structural integrity of the joint. In fact, it protects
synovial cells and controls the movement of large
molecules in the joint, preventing the release of
free radicals and inflammatory factors. More-
over, IA HA-related decreases in pain have been
associated with reduced production of brady-
kinin, prostaglandin E2, and substance P, and the
direct inhibition of nociceptive afferents.[49,50]
Injection of exogenous HA into a joint may
restore the articular viscoelastic properties.[51] A
possiblemechanism that describesHA therapeutic
action in OA has been proposed. Macroscopical-
ly, HA restores the synovium and the organiza-
tion of healthy cartilage so that the joint can react
viscoelastically to force application.[52,53] HA ex-
erts a beneficial effect on the cartilage integrity
and response to OA damage, which may be re-
lated to a primary effect of HA on the cartilage
surface. HA may also act on the synovial mem-
brane by limiting the synovial reaction. HA exerts
a chondroprotective action, which can be explained
at different levels. It seems to have a trophic effect
on chondrocytes, enhancing their metabolism.
Moreover, HA inhibits the development of the
fibroblast-like cells in damaged joints.[54] HA pro-
tects chondrocytes from oxidative stress through
preservation of mitochondrial function,[55] and it
inhibits apoptotic and dedifferentiative effects of
nitic oxide (NO) on chondrocytes, reverting the
block of protein kinase C-a.[56,57]
In addition, HA therapeutic effects can also be
explained at the molecular level. In fact HA treat-
ment decreases the expression of vascular endo-
thelial growth factor (VEGF), VEGF receptor,
and connective tissue growth factor (CTGF), which
are known to be significantly upregulated in OA
causing detrimental effects on cartilage.[58,59]
VEGF induces capillary formation and is in-
volved in the inflammatory process, while CTGF
stimulates MMP-3 and cellular matrix degrada-
tion.[60-63] HA also inhibits IL-1b preventing
MMP-1 and MMP-9 release, and it increases the
cartilage catabolism of the joint.[43-45,62]
These effects may depend on the HA molec-
ular weight and the duration of time that HA is
present within the joint space.[52,64-66] There
is evidence that injected HA remains within the
joint space for hours or even days, and that
it exerts its clinical effects for months, possibly
due to its anti-inflammatory and anti-nociceptive
properties.[67,68]
The ability of HA to bind to its cellular re-
ceptors is strictly related to its molecular size, so
that LMWHA elicits a cellular response opposite
to that ofHMWHA.Experimental animalmodels
of OA showed that HA with a molecular weight
within the range 0.5–1.0 million Da was responsi-
ble for more effective reductions in indices of
synovial inflammation, and greater restoration of
SF rheologic properties (visco-induction) thanHA
with a molecular weight >2.3 million Da.[52] It was
also observed that, although HA with a molecular
weight >40kDa produced an analgesic effect, HA
with a molecular weight of 860 or 2300kDa pro-
duced high and long-lasting analgesia. These ef-
fects of HA appear to be caused by the interaction
between HA and its receptors.[69]
The effects of HA on human OA chondrocytes
are also related to its molecular weight, so that
the 500–730 kDa HA at 200 mg/mL reduces the
synthesis of both IL-1-induced NO and prosta-
glandin E2 by 70% and 45%, respectively, while
the 6000 kDa HA does not.[70]
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2.3 Clinical Use
Pure high molecular weight hyaluronan was
first developed by Balazs[71] in the 1960s. It was
known as non-inflammatory fraction sodium
hyaluronan (NIF-NaHA) and was marketed for
use in ocular surgery. Hyaluronan was injected
into the joints of racehorses for traumatic OA
with effective results,[72] leading to the first use of
viscosupplementation for human knee OA in the
early 1970s.[73]
The clinical use of viscosupplementation to
treat OA in humans is growing worldwide. The
procedure involves the introduction of HA into
the joint, and aims to provide initial lubrication
and shock absorption, and to change the long-
term disease process, thereby restoring the rheo-
logic properties of the SF.[74]
During the last 20 years, several clinical trials
using different HA formulations (LMW HA has
been commonly used; and less often, HMW HA
has been injected) have shown that HA is more
active than placebo in reducing arthritic pain.[17,75,76]
In a literature review conducted by Brzusek and
Petron[77] that used data from all MEDLINE- or
Embase-identified randomized, placebo-controlled
trials involving the use of hyaluronans, HA and
sodium hyaluronate plus hylan G-F 20 (a cross-
linked HA derivative, approved by the US FDA
since 1997 for the treatment of patients with symp-
tomatic knee OA) were both associated with signif-
icant improvements in pain and physical function
in patients (mostly adults aged over 40 years) with
knee OA. Both regimens were most effective be-
tween 5 and 13 weeks after injection, but improve-
ments were also observed at 14–26 weeks and
sometimes even longer; both were well tolerated
with a low incidence of adverse events. Moreover,
the same authors also reported beneficial treat-
ment effects when HA was coadministered with
other therapies, and concluded that the drug was
not only effective, but also safe and tolerable for
the treatment of symptomatic knee OA.
A recent systematic review of randomized, con-
trolled, prospective clinical studies (eight trials;
n= 1674 patients), showed that hylan G-F 20 sig-
nificantly improvedWesternOntario andMcMaster
Universities (WOMAC)OA index physical function
versus appropriate/conventional care or corticoster-
oid treatment. Moreover, hylan G-F 20 was asso-
ciated with a significant improvement in loss of
activity compared with saline, and with similar func-
tional improvements compared with progressive
knee exercises or NSAIDs.[78]
In a 2008 literature review of all trials involv-
ing the use of hylan G-F 20, the authors con-
cluded that the clinical use of this drug was safe
and effective for decreasing pain and improving
function in patients experiencing knee OA.[79]
A systematic review and meta-analysis com-
paring the efficacy of IA HA with that of corti-
costeroids for knee OA (seven trials; n = 606
patients), showed that corticosteroids were more
effective than HA in the short term (up to
4 weeks), but that HA was more effective in the
long term (4–26 weeks). This highlights the im-
portance of determining whether coadministra-
tion of the two agents may lead to a synergistic
effect useful in clinical practice.[80]
In addition, it has been pointed out that HA
may relieve pain and improve function in patients
with hip OA. Moderate improvements in pain
and function were reported for 3–6 months after
HA injection, with no serious adverse events ob-
served.[81]
All the clinical trials involving the use of HA in
knee, carpometacarpal joint, temporomandibular
joint, and ankle OA are summarized in tables sI,
sII, sIII, and sIV (see Supplemental Digital Con-
tent 1, http://links.adisonline.com/DRZ/A2). Table
sV (Supplemental Digital Content) summarizes all
the other applications of HA in clinical studies.
3. Intra-Articular Injections: Other Drugs
3.1 Corticosteroids
The efficacy and safety of IA corticosteroids
in the treatment of knee OA was evaluated by
Bellamy et al.[82] in 2006. This Cochrane system-
atic review analyzed results from 28 trials
(n = 1973), which compared IA corticosteroids
with placebo, IA HA/hyaluronan/hylan, joint
lavage, or other IA corticosteroids. This review
showed that IA corticosteroids were more effec-
tive than IA placebo for pain reduction and
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functional improvement (patient global assess-
ment) at 1 week post-injection. There was evi-
dence of a between-group difference in pain re-
duction at 2 weeks post-injection that was in
favor of corticosteroids, but not of a significant
between-group difference in functional improve-
ment. At 4–24 weeks post-injection, there was no
evidence of a between-group difference in the effect
on pain or function.
Comparing corticosteroids with HA products,
no statistically significant differences were de-
tected at 1–4 weeks post-injection, according to
the Cochrane systematic review.[83] However,
between 5 and 13 weeks post-injection, HA
products were more effective than corticosteroids
for one or more of the following variables:
WOMAC osteoarthritis index, Lequesne Index,
pain, range of motion (flexion), and number of
responders. In one study,[83] there was also a
between-group difference in the range of motion
(flexion) at 14 and 26 weeks that was in favor of
HA, but no differences in efficacy were detected
at 45–52 weeks. In general, HA products and IA
corticosteroids had a similar onset of effect, but
HA products had a more durable response.
In the Cochrane systematic review,[82] compar-
isons between various IA corticosteroids showed
that triamcinolone hexacetonide was superior to
betamethasone with regard to the number of pa-
tients reporting pain reduction up to 4 weeks
post-injection. Comparisons between IA cortico-
steroid and joint lavage showed no differences in
any of the efficacy or safety outcome measures.
In another systematic literature review con-
ducted in 2009, the efficacy (including duration of
action) of IA corticosteroid injections in reducing
pain caused by knee OA was assessed. This re-
view analyzed data from six trials (reported in
five articles) that compared IA corticosteroids with
placebo, and four articles that compared different
IA corticosteroids. The review observed that IA
corticosteroids were associated with reductions in
knee pain that lasted for at least 1 week. It conclud-
ed that IA corticosteroids can only be considered
as a short-term treatment for a chronic problem.
Two of four trials showed triamcinolone to be
more effective in pain reduction than the other
corticosteroids assessed.[84]
In a review of the literature that included
results from eight trials (four randomized con-
trolled trials) examining the efficacy of IA corti-
costeroid injection for hip OA, there was strong
evidence to support the use of corticosteroid in-
jections for short-term reductions in pain, and in
patients refractory to non-pharmacologic thera-
py or pharmacologic therapy with analgesic or
NSAID therapy. The authors reported that,
when an IA hip injection is performed, the use of
radiological guidance is recommended. The same
review reports a comprehensive list of contra-
indications for IA hip corticosteroid injection,
which include suspected or known joint infection,
presence of joint fracture, coagulopathy, overly-
ing cellulitis or infection, hypersensitivity to cor-
ticosteroids, and the presence of a prosthetic
joint. Relative contraindications include anti-
coagulation therapy, joint instability, poorly
controlled diabetes mellitus, and adjacent skin
abrasions. Adverse effects related to IA injections
of the hip are septic arthritis, osteonecrosis, and
the risk of joint infection after total hip replace-
ment following pre-operative IA corticosteroid
injection.[85]
A postoperative, IA methylprednisolone and
lidocaine injection in 58 patients with chondro-
malacia undergoing meniscectomy was tested in a
randomized controlled trial. The patients were
randomized to receive active treatment (n = 29) or
saline plus lidocaine (n = 30). Results showed that
the addition of a postoperative corticosteroid in-
jection improved pain relief and function at an
early timepoint, but did not provide a lasting ef-
fect compared with a local anesthetic injection.[86]
A dual-center, single blind, randomized, parallel-
group trial was performed to compare the benefits
of IA corticosteroid (40mg triamcinolone acetonide
and 1% lidocaine) injections and tidal irrigation (TI)
in patients with OA of the knee.[87] TI is the re-
peated distention and irrigation of a joint with sa-
line through a 14 gauge Vere’s needle.[88] In this
study, the Vere’s needle was introduced using a
3.2mm arthroscope under local anesthesia.[87]
Patients were followed up for 6 months. Both pro-
cedures provided significant short-term pain relief
of at least 4 weeks duration in >80% of patients,
and TI displayed a significantly greater duration of
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benefit than IA corticosteroid therapy (statistical
analyses not available). Patients with effusions and
milder radiographic change obtained the best re-
sponse to treatment. Both treatments were well
tolerated with few adverse effects. The benefits of
corticosteroid injection were seen most greatly in
patients with milder radiographic OA, and in those
with a clinically detectable effusion.[87]
3.2 Analgesics/Anti-Inflammatory Drugs
The efficacy and safety of an IA cocktail an-
algesic injection was assessed in a randomized,
double-blind, placebo-controlled, parallel-group
study in 80 patients with OA undergoing unilat-
eral total knee arthroplasty (TKA). Patients in
this study received an IA intraoperative injection
containing 5mg morphine, 30mg bupivacaine
(mg/1.5mL), and 1 mL betamethasone (mixed
with sterile normal saline solution to make up
a combined volume of 60mL) or normal saline
as control. In this study, the IA cocktail analgesic
injection significantly (p < 0.05) reduced the mor-
phine consumption during the 0–36 hours
postoperative period and the total morphine
consumption. Visual analog scale (VAS) was
significantly (p < 0.05) lower in the trial group
than in the control group at rest (6, 10, 24, and
36 hours postoperatively) and during exercise
(24 and 36 hours postoperatively). In addition,
active treatment was better than placebo with
regard to other study endpoints, including time to
perform an active straight leg raise, time to ac-
tively reach 90 knee flexion, and the range of
motion of the knee on postoperative day 15. The
occurrence of nausea and vomiting in the trial
group was lower than in the control group.
Overall, this study demonstrated that use of an IA
injection containing a cocktail of analgesics fol-
lowing TKA reduces the need for morphine, and
offers better pain control than placebo without
any apparent risks.[89]
Another randomized, double-blind study
(n = 39) assessed the efficacy of IA morphine
(1mg [1mL] of morphine diluted in 9mL of sal-
ine [group 1]) and that of bupivacaine (25mg
[10mL] of 0.25% bupivacaine without epi-
nephrine [group 2]) on the joint flexion and ex-
tension angles (among other endpoints) of
patients with knee OA. Mean angle of flexion or
extension of the knee significantly increased from
baseline to endpoint in both treatment groups
(p £ 0.05). Furthermore, the analgesic effects of
both drugs were similar, with both significantly
reducing pain at rest and during movement
(p£ 0.05).[90]However, no significant between-group
differences were observed for any endpoint.
Thirty patients with an acute effusion of the
knee joint that was related to grade II–III OA
(according to the Kellgren-Lawrence system)
were randomly assigned to receive either an IA
injection of tenoxicam 20mg following aspiration
or oral tenoxicam 20mg/day for 10 days (n = 15 in
each group). The study showed that IA injection
of tenoxicam provided rapid pain relief in
patients with an acute flare-up of knee OA. It also
showed that IA tenoxicam helped to prevent ef-
fusion, with the number of knee effusions being
significantly (p < 0.01) lower in the IA treatment
group than in the oral treatment group 1 year
after treatment.[91]
3.3 Polymerized Collagen
The efficacy of polymerized type I collagen
(polymerized collagen; a compound that has anti-
inflammatory and tissue regeneration properties)
was investigated in a study involving 53 patients
with knee OA. Patients in this trial were treated
with 12 IA injections of 2 mL of polymerized
collagen (n = 27) or 2mL of placebo (n = 26).
Polymerized collagen was safe and well tolerated,
and patients in the polymerized collagen group
had statistically (p < 0.05) greater improvements
in primary outcomes (i.e. Lequesne index,WOMAC
OA index, and VAS) from baseline to follow-up
(at 3–6 months, depending on endpoint) than those
in the placebo group.[92]
3.4 Stem-Cell Therapy
The development of techniques that cause
multipotent adult mesenchymal stem cells (MSCs)
to differentiate into cells of the chondrogenic lin-
eage have led to new insights in the attempt to
restore the damaged cartilage in OA patients. It
has been proposed that MSCs may be used as
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progenitor cells to engineer cartilage implants that
can be used to repair chondral and osteochondral
lesions, and as trophic producers of bioactive
factors to initiate endogenous regenerative activ-
ities in the OA joint.[93] No¨th et al.[83] proposed
that MSCs may be delivered to the point of action
by direct IA injection or by graft of engineered
constructs derived from cell-seeded scaffolds.
3.5 Anti-Cytokine Drugs
Anakinra, a recombinant IL-1 receptor antag-
onist, at a dose of 50 or 150mg was well tolerated
as a single IA injection in a multicenter, double-
blind, placebo-controlled study involving pa-
tients with OA of the knee. However, over a
12-week follow-up period, the drug was not
associated with improvements in OA symptoms
compared with placebo.[94]
Orthokin, a product that is produced by
incubating whole human venous blood with
CrSO4-treated glass beads, has previously dem-
onstrated the ability to increase IL-1 receptor
antagonist production in vitro.[95] In a randomized,
multicenter, double-blind, placebo-controlled trial
involving 167 patients with symptomatic knee OA,
patients received six IA injections of Orthokin or
physiologic saline. Study results showed sig-
nificantly greater improvements with Orthokin
than with placebo in the Knee injury and Osteo-
arthritis Outcome Score (KOOS)-assessed symp-
tom (p= 0.002) and sport parameters (p= 0.042).
Furthermore, the biologic response induced by
Orthokin in this trial was different to that in-
duced by placebo.[96]
In a pilot study involving ten women
(12months’ follow-up), the effect of IA infliximab
on erosive OA of the hands was evaluated.
Patients with bilateral hand OA received monthly
IA injections of infliximab (a monoclonal anti-
body against TNF-a) in the most involved hand,
and of physiologic saline in the other hand (con-
trol). VAS for spontaneous pain at baseline was
significantly (p< 0.01) higher for the hand treated
with IA infliximab than for the control hand.
IA infliximab was associated with reductions in
VAS for spontaneous pain at 6 months, with the
difference from baseline becoming significant
(p< 0.002) at 12 months. Similar results were
obtained in the evaluation of pain on lateral
pressure. Furthermore, on radiologic evaluation,
there was a difference between infliximab- and
saline-treated joints in the progression of the
anatomical lesion progression score that was in
favor of infliximab, and a tendency towards sta-
bility or slight bone remodeling in the infliximab
group compared with a tendency towards a wor-
sening in the saline group. The treatment showed
no side effects or local adverse reactions, and the
hematochemical parameters showed no signif-
icant modifications and remained within the nor-
mal range.[97]
3.6 Neurotransmitter Antagonists
Recently, the efficacy and safety of botulinum
toxin type A (BoNT-A) injected IA have been
evaluated in 60 patients with moderate pain and
functional impairment secondary to knee OA. In
this double-blind, randomized, single tertiary
care academic medical center trial with 6-month
follow-up, patients were randomized to receive a
single injection of corticosteroid, low-dose BoNT-A
(100 units), or high-dose BoNT-A (200 units). It
was observed that VAS score decreased within each
group, reaching statistical significance (p= 0.01)
only in the low-dose BoNT-A group at 8 weeks. In
addition, all groups showed statistically significant
improvements in WOMAC OA index scores (pain,
stiffness, function) at 8 weeks (p-value not avail-
able), and no serious adverse events were noted in
any group.[98]
3.7 Bisphosphonates
In a phase II, randomized, partially-blind
clinical trial, 150 patients (aged 50–75 years) with
primary knee OA were randomized to one of the
following five IA therapies: (i) clodronate 0.5mg,
one IA injection/week for 4 weeks; (ii) clodronate
1mg, one IA injection/week for 4 weeks; (iii) clo-
dronate 2mg, one IA injection/week for 4 weeks;
(iv) clodronate 1mg, two IA injections/week for
2 weeks (clodronate 1 + 1mg); or (v) HA 20mg,
one IA injection/week for 4 weeks. In all treat-
ment groups, significant (p< 0.001) improvements
in VAS for different types of pain and the Lequesne
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index were reported after the first injection and
continued to improve for up to 2–4 weeks after
the last injection; however, no significant between-
group differences were noted for the latter results.
A significant (p= 0.03) linear trend for a dose-
response (0.5–2mg clodronate) relationship was
found for active movement VAS pain. In addition,
both joint extension and mobility scores improved
significantly from baseline at all timepoints in all
treatment groups, although no between-group dif-
ferences were seen (p-values ranging from 0.06 to
0.34). These results indicate that both IA clodronate
and HA provide symptomatic and functional
improvements in knee OA.[99]
4. Discussion
The best treatment for OA is not yet clear, and
an early diagnosis still plays a key role in the
management of this condition. Current OARSI
(Osteoarthritis Research Society International)
recommendations for the optimal management
of patients with hip or knee OA were summarized
by Zhang et al.,[100] and include a combination of
both non-pharmacologic and pharmacologic mo-
dalities of therapy that are based on a critical ap-
praisal of existing guidelines, a systematic review
of research evidence, and the consensus opinions
of an international, multidisciplinary group of
experts. These recommendations create evidence-
based and consensus guidelines for the treatment
of knee and/or hip OA, providing assistance to
physicians and allied healthcare professionals
who deal with patients with these conditions in
both primary and secondary care settings.
The recommendations are as follows:[100]
(i) 11 non-pharmacologic modalities, including ed-
ucation and self-management; regular telephone
contact; referral to a physical therapist; aerobic,
muscle strengthening, and water-based exercises;
weight reduction; walking aids; knee braces;
footwear and insoles; thermal modalities; trans-
cutaneous electrical nerve stimulation; and acu-
puncture; (ii) eight pharmacologic modalities,
including acetaminophen (paracetamol); cyclo-
oxygenase-2 (COX-2) non-selective and selective
oral NSAIDs; topical NSAIDs and capsaicin;
IA injections of corticosteroids, IA injections of
hyaluronates; glucosamine and/or chondroitin
sulfate for symptom relief; glucosamine sulfate,
chondroitin sulfate, and diacerein for possible
structure-modifying effects; and opioid analge-
sics for the treatment of refractory pain; and
(iii) five surgical modalities, including total joint
replacements; unicompartmental knee replacement;
osteotomy and joint preserving surgical procedures;
joint lavage and arthroscopic debridement (in knee
OA); and joint fusion as a salvage procedure when
joint replacement has failed.
In the past, OA was not considered an inflam-
matory disorder, but nowadays it is associated
with several inflammatory mediators. Finding a
way to modulate these inflammatory mediators
could lead to new insights into the treatment of
this pathologic condition (see figure s1 in the
Supplemental Digital Content).
Recently, a systematic review examined the
influence of the ‘placebo effect’ (defined as the
change in various efficacy endpoint parameters
from baseline to study end in the placebo group)
on the management of OA in 198 randomized,
placebo-controlled trials (including a total of 193
placebo groups [n = 16 364] and 14 untreated con-
trol groups [n = 1167]) investigating the use of a
broad range of OA therapies (non-pharmacologic,
pharmacologic, and surgical treatments). The au-
thors pointed out that it is difficult to distinguish
this change from natural disease remission and
chance regression to the mean. According to this
review, placebo effectively relieved pain, and im-
proved patient function and stiffness. In partic-
ular, the review showed that the pain-relieving
effect of placebo increases when the active treat-
ment effect, baseline pain level, or sample size in-
creases, and when placebo has been given as an
injection.[101]
Although some active compounds are rapidly
cleared from the OA joint, meaning that multiple
injections are required with the subsequent
potential for an increased incidence of adverse
effects (e.g. infection and joint disability), IA
injections offer several benefits for the treatment
of OA. These benefits include the ability to reach
high drug concentrations at the site of delivery,
use drugs with low bioavailability, and limit the
occurrence of adverse effects related to systemic
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administration. However, although rare, com-
plications of IA injections, such as infection,
post-injection flare, crystal-induced synovitis,
cutaneous atrophy, and steroid arthropathy may
occur. The incidence of septic joints related to
local corticosteroid injection is about 1 in 10 000
injections, while for post-injection flare, the fre-
quency is around 200 in 10 000. Due to the crys-
talline nature of corticosteroids, crystals present
in the joint produce transient synovitis in about
10% of patients; however, this condition gen-
erally disappears after a few days.
Because IA injection is an invasive procedure,
it has the disadvantage of being painful and put-
ting the patient at risk of infection.[102] As for any
IA joint injection, various adverse effects may
occur with IA joint injections, such as injection-
related pain, post-injection flare, skin pigment
changes, fat atrophy, and joint infection. System-
ic effects can also occur, including disruption of
diabetes and hypertension control, facial flush-
ing, inhibition of the hypothalamo-pituitary-
adrenal axis, sepsis, and death.[103-106] Prefilled
syringes, rigorous asepticmaneuvers, proper needle
choice, and isotonicity (a pH of 7.4 or sometimes
less can stabilize the drug without activating in-
flammatory enzymes) are all techniques that may
help to reduce the risk of adverse effects.
There is also evidence to suggest that sonog-
raphic needle guidance of IA injections improves
performance and clinical outcomes. In a random-
ized controlled study, patients with painful joints
(n = 148) received IA injections under sono-
graphic guidance, or by the conventional pal-
pation-guided anatomic technique. Relative to
the conventional technique, sonographic guid-
ance resulted in a 43.0% reduction in procedural
pain (p < 0.001), a 58.5% reduction in absolute
pain scores at 2 weeks (p < 0.001), a 75.0% reduc-
tion in VAS-assessed significant pain (p < 0.001),
a 25.6% increase in the responder rate (defined as
a reduction in VAS score from baseline of ‡50%;
p< 0.01), and a 62.0% reduction in the non-
responder rate (defined as a reduction in VAS
score from baseline of <50%; p < 0.01). The sono-
graphic-guided technique also increased the
number of effusions detected by 200% and the
volume of aspirated fluid by 337%.[107]
When choosing the optimal drug or drug com-
bination for IA injection, the experience of each
doctor, and individual factors (e.g. bioavailabil-
ity and mechanism of action) must be considered.
In our opinion, the short- and long-term per-
spective must be taken into account when select-
ing IA treatment. When the short-term approach
is required (e.g. for the treatment of painful acute
conditions), SF aspiration under local anesthetic
is mandatory. If long-term IA therapy is re-
quired, the SF will decrease after the first set of
injections, allowing the subsequent ones to be
directly performed within the joint.
Among various treatment choices (oral, par-
enteral, or IA drugs), viscosupplementation with
hyaluronans seems to be a promising option for
the treatment of OA (sections 2.2.1 and 2.3). This
technique aims to replace HA, which is reduced
in the OA process, and restore the elasticity and
viscosity of the SF back to normal. Although a
review described earlier underlines the impor-
tance of taking into account the ‘placebo effect’
when speaking of IA injections,[101] literature
supports the use of HA in the treatment of OA
because of its immediate bioavailability and the
absence of systemic effects, and its use should be
encouraged.
HA plus corticosteroid therapy should form
part of the short-term treatment plan for OA in
order to take control of the acute inflammatory
process as soon as possible. Fixing a bandage to
the joint and rest should complete the procedure.
In the follow-up, and depending on results from
the SF examination and the local and general
symptoms, the doctor should select the best pro-
cedure to repair or regenerate the synovial mem-
brane and cartilage, preventing or delaying further
relapse episodes. At this time, HA alone or
in combination with other compounds contain-
ing methotrexate, biphosphonates, somatostatin,
NSAID, or biotechnologic products, should be
selected, with administration frequency and dos-
ages being determined according to the phys-
iopathology of the disease and instrumental
imaging of the process at follow-up.
Our efforts are now targeted at improving the
drug delivery systems, such as drains, double-
chamber syringes, dedicated needles or catheters,
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and kits for the joint medication, in order to
achieve the patient’s best compliance and the
doctor’s optimal standardized operative strate-
gies. Joint care is a well defined area of the rheu-
matologic, orthopedic, and physiatric specialties
and requires proper tools, medications, and ho-
mogenous treatment planning to standardize the
evidence-based results.
In summary, IA HA has numerous restorative
effects in patients with acute or chronic joint dis-
ease. In our opinion, to achieve the most effective
outcome, an individually tailored approach should
be taken for each case. For this reason, further
investigation into different HA formulations (in-
cluding crosslinked and non-crosslinked formula-
tions), and their synchronous or metachronous
associationwith other compounds, is of importance.
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